Dashboard
Manage Tickers

TCRX TScan Therapeutics, Inc.

Nasdaq tscan.com


$ 1.13 $ 0.00 (0 %)    

Monday, 10-Nov-2025 07:30:41 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 618.74 $ 0.00 (0 %)
DIA $ 471.70 $ 0.00 (0 %)
SPY $ 677.00 $ 0.00 (0 %)
TLT $ 89.11 $ 0.00 (0 %)
GLD $ 376.66 $ 0.00 (0 %)
$ 1.09
$ 1.16
$ 1.10 x 300
$ 1.15 x 338
-- - --
$ 1.02 - $ 6.04
727,780
na
61.86M
$ 0.66
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-05-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-06-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-09-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-19-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-kimberly-clark-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday
This Kimberly-Clark Analyst Is No Longer B...
11/04/2025 11:56:53

btig-downgrades-tscan-therapeutics-to-neutral
BTIG Downgrades TScan Therapeutics to Neutral
11/04/2025 11:23:31

BTIG analyst Justin Zelin downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral.

needham-maintains-buy-on-tscan-therapeutics-lowers-price-target-to-6
Needham Maintains Buy on TScan Therapeutic...
11/04/2025 10:30:35

Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $9 to $6.

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
11/03/2025 17:05:47

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
11/03/2025 12:05:47

tscan-therapeutics-reaches-agreement-with-fda-on-tsc-101-study-design-announces-30-workforce-reduction-to-focus-on-heme-program-and-prioritization-of-advancing-tsc-101
TScan Therapeutics Reaches Agreement With ...
11/03/2025 11:34:57

tscan-therapeutics-to-present-new-research-on-t-cell-therapies-at-acr-convergence-2025-in-chicago
TScan Therapeutics To Present New Research...
09/17/2025 11:03:34

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (T...

tscan-therapeutics-q2-eps-028-inline-sales-3076m-beat-1405m-estimate
TScan Therapeutics Q2 EPS $(0.28), Inline,...
08/12/2025 11:12:59

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This ...

what-analysts-are-saying-about-tscan-therapeutics-stock
What Analysts Are Saying About TScan Thera...
05/07/2025 13:00:52

hc-wainwright--co-maintains-buy-on-tscan-therapeutics-lowers-price-target-to-10
HC Wainwright & Co. Maintains Buy on TScan...
05/07/2025 12:26:11

HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price ...

tscan-therapeutics-q1-eps-026-beats-029-estimate-sales-217m-beat-110m-estimate
TScan Therapeutics Q1 EPS $(0.26) Beats $(...
05/06/2025 11:03:30

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(...

tscan-therapeutics-to-present-at-the-american-society-of-gene-and-cell-therapy-28th-annual-meeting
TScan Therapeutics To Present At The Ameri...
04/28/2025 20:57:35

expert-outlook-tscan-therapeutics-through-the-eyes-of-5-analysts
Expert Outlook: TScan Therapeutics Through...
04/08/2025 13:00:30

needham-reiterates-buy-on-tscan-therapeutics-maintains-9-price-target
Needham Reiterates Buy on TScan Therapeuti...
04/08/2025 12:46:28

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9 price target.

barclays-maintains-overweight-on-tscan-therapeutics-lowers-price-target-to-3
Barclays Maintains Overweight on TScan The...
03/07/2025 11:29:41

Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lowers the price target from ...

breaking-down-tscan-therapeutics-4-analysts-share-their-views
Breaking Down TScan Therapeutics: 4 Analys...
03/06/2025 12:00:25

hc-wainwright--co-reiterates-buy-on-tscan-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on TSca...
03/06/2025 11:59:37

HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price t...

needham-maintains-buy-on-tscan-therapeutics-lowers-price-target-to-9
Needham Maintains Buy on TScan Therapeutic...
03/05/2025 16:36:31

Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $11 to $9.

tscan-therapeutics-q4-2024-gaap-eps-030-misses-027-estimate-sales-66500k-miss-135m-estimate-cash-cash-equivalents-and-marketable-securities-of-2901m-to-fund-operations-into-q1-of-2027
TScan Therapeutics Q4 2024 GAAP EPS $(0.30...
03/05/2025 12:12:12

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of ...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
12/26/2024 21:05:44

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION